Inhibitor Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	0.52	2.38	5.61	8.84	11.95	0.03
Cash & Short-Term Investments	0.52	2.38	5.61	8.84	11.95	0.03
Cash Growth	-86.20%	-57.63%	-36.57%	-26.03%	38923.13%	-59.20%
Prepaid Expenses	0.07	0.07	0.09	0.11	0.02	0.03
Total Current Assets	0.59	2.45	5.69	8.95	11.98	0.06
Property, Plant & Equipment	0.05	0.06	-	-	-	-
Total Assets	0.64	2.51	5.69	8.95	11.98	0.06
Accounts Payable	0.14	0.05	0.02	0.03	0.15	0.28
Accrued Expenses	0.01	0.69	0.69	0.63	0.12	0.07
Current Portion of Long-Term Debt	-	-	-	-	0.41	0.23
Current Portion of Leases	0.03	0.02	-	-	-	-
Other Current Liabilities	-	-	-	-	-	0.1
Total Current Liabilities	0.17	0.77	0.71	0.67	0.68	0.68
Long-Term Leases	0.02	0.04	-	-	-	-
Long-Term Unearned Revenue	3	3	3	3	3	3
Total Liabilities	3.2	3.8	3.71	3.67	3.68	3.68
Common Stock	0.02	0.02	0.02	0.02	0.02	0.04
Additional Paid-In Capital	54.14	54.11	54.09	54.05	54.03	50.05
Retained Earnings	-56.72	-55.42	-52.12	-48.78	-45.75	-57.67
Total Common Equity	-2.56	-1.29	1.99	5.28	8.3	-7.58
Shareholders' Equity	-2.56	-1.29	1.99	5.28	8.3	-3.62
Total Liabilities & Equity	0.64	2.51	5.69	8.95	11.98	0.06
Total Debt	0.05	0.06	-	-	0.41	0.23
Net Cash (Debt)	0.47	2.31	5.61	8.84	11.54	-0.2
Net Cash Growth	-87.22%	-58.73%	-36.57%	-23.40%	-	-
Net Cash Per Share	0.00	0.01	0.03	0.05	0.03	-0.00
Filing Date Shares Outstanding	173.79	172.57	172.32	172.02	171.79	376.86
Total Common Shares Outstanding	173.79	172.57	172.32	172.02	171.79	376.86
Working Capital	0.41	1.68	4.99	8.28	11.3	-0.62
Book Value Per Share	-0.01	-0.01	0.01	0.03	0.05	-0.02
Tangible Book Value	-2.56	-1.29	1.99	5.28	8.3	-7.58
Tangible Book Value Per Share	-0.01	-0.01	0.01	0.03	0.05	-0.02